In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Next generation sequencing (NGS), or massively parallel sequencing, refers to high-throughput methods for DNA sequencing that are not Sanger-based, based on clonally amplified DNA templates or single DNA molecules rather than electrophoretic separation of chain-termination products produced in individual sequencing reactions. GlobalData uses proprietary data and analytics to provide a comprehensive report on the next generation sequencing devices market, including market shares of different players within China. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the next generation sequencing market in China was Illumina followed by Burning Rock Biotech, Thermo Fisher Scientific, Qiagen, Agilent Technologies, New England Biolabs, Amoy Diagnostics and F. Hoffmann-La Roche.
NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. The technique is highly scalable and typically involves fragmenting the genome and then randomly sampling for and sequencing these fragments. NGS can be performed on formalin-fixed and paraffin-embedded (FFPE) and freshly collected tissue specimens and on fine-needle aspiration samples and small biopsy specimens. NGS encompasses a number of different sequencing platforms; whole-genome sequencing, exome sequencing, transcriptome sequencing (mRNA sequencing), and targeted sequencing of multigene panels, all of which simultaneously sequence millions of DNA fragments and later reply on bioinformatics analysis to map these reads to a human reference genome. In this model, GlobalData has considered pyrosequencing reagents to be NGS tests.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the next generation sequencing devices market within China was expected to be over $5m in 2022.
For the latest complete market share analysis of next generation sequencing device market in China, buy the report here.